Center on Health Equity and Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Partners

Press Releases

Product Approvals and Launches

Media

Clinical Spotlight

Enduring Webinars

Guidelines

Insights

Interviews

Microsites

News Network

OnLocation

Payer Perspectives

Peer Exchange

Podcasts

Post Conference Perspectives

Stakeholder Summit

Week in Review

Conferences

Conference Coverage

Conference Listing

Journals

Submit a Manuscript

All Journals

The American Journal of Managed Care

The American Journal of Accountable Care

Evidence-Based Oncology

Supplements and Featured Publications

Compendia

ALL/AML

Alopecia

Asthma

Atopic Dermatitis

Autoimmune

Biosimilars

Breast Cancer

CLL/SLL

COPD

COVID-19

Cardiovascular

Colorectal Cancer

DLBCL

Dermatology

Diabetes

Duchenne Muscular Dystrophy

Employers

Gastroenterology

Gene Therapy

Graft-vs-Host Disease (GVHD)

Heart Failure

Hemophilia

Idiopathic Pulmonary Fibrosis

Immuno-Oncology

Immunology

Leukemia and Lymphoma

Liver Cancer

Lung Cancer

Medicare

Mental Health

Multiple Myeloma

Multiple Sclerosis

Myasthenia Gravis

Myelodysplastic Syndromes

Myeloproliferative Neoplasms (MPN)

Non–Small Cell Lung Cancer

Obesity

Oncology

Ophthalmology

Ovarian Cancer

Population Health

Psoriasis

Pulmonary Arterial Hypertension

Rare Blood

Reimbursement

Skin Cancer

Sleep

Soft Tissue Sarcoma

Type 1 Diabetes

Events

Upcoming Webinars

CME/CE

Resources

Exclusive Content

Formulary Central

Interactive Tools

Subscribe

Articles

Results from a study presented at the Academy of Managed Care Pharmacy 2024 annual meeting demonstrated sustained efficacy of bimekizumab compared with placebo in patients with non-radiographic and radiographic axial spondyloarthritis (axSpA) at week 52.

Bimekizumab Shows Sustained Efficacy in Treating Axial Spondyloarthritis for 52 Weeks

A team of researchers developed 3 quality improvement measures embedded in electronic health records (EHRs) to improve care delivery in patients with heparin-induced thrombocytopenia.

EHR Alerts Improve Quality of Care in Heparin-Induced Thrombocytopenia, Study Finds

Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.

She has a BA in English from Penn State University. You can connect with Maggie on 

Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.


Forging a Patient-Centric Path to Revolutionize and Redefine Value-Based Care

The multi-year collaboration aims to develop tolerizing vaccines for up to 3 autoimmune diseases. 

Bristol Myers Squibb, Repertoire Enters $1.8 Billion Deal to Develop Vaccines for Autoimmune Diseases 

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About Us

Contact

Editorial Staff

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Stakeholders

Academia

Health System

Payers

Providers

Topics

Institute for Value-Based Medicine

All Coverage

Event Coverage

About AJMC

AJMC Journals

Anniversary

Author Forms

Authors

Nominate a Rising Leader

Brian LaMoreaux, MD, MS, explains the differences between gout and uncontrolled gout and the symptoms and complications associated with these diseases.

Episode 1: What do gout and uncontrolled gout look like?

Brian LaMoreaux, MD, MS, discusses how gout progresses and what a patient’s experience with uncontrolled gout might look like.

Episode 2: How does gout progress?

Brian LaMoreaux, MD, MS, explains the signs and symptoms of gout that are caused by urate deposition and how urate-lowering therapy works to reduce serum uric acid levels.

Episode 3: What is the role of urate deposition in gout disease progression?

Brian LaMoreaux, MD, MS, describes the short- and long-term effects of uncontrolled gout, including flares, inflammation, bone erosion, and joint damage.

Episode 4: What are the short- and long-term effects of uncontrolled gout, especially when treatment is ineffective?

Brian LaMoreaux, MD, MS, explains a two-pronged pharmacotherapy approach and the 2020 American College of Rheumatology Guideline for the Management of Gout.

Episode 5: What are some recommended treatment approaches for chronic gout?

Brian LaMoreaux, MD, MS, discusses the treatment landscape for uncontrolled gout, including data on treatment usage and managing patients’ serum uric acid levels.

Episode 6: What does the treatment landscape for uncontrolled gout look like?

Brian LaMoreaux, MD, MS, discusses different urate-lowering options for uncontrolled gout and their limitations.

Episode 7: What are some medication considerations for patients with uncontrolled gout?

Brian LaMoreaux, MD, MS, answers frequently asked questions, with topics including: how to define uncontrolled gout, how to differentiate between gout and uncontrolled gout, how gout flares are documented in the absence of a specific ICD code for flares, and what patients with uncontrolled gout need to achieve the best outcomes.

Episode 8: Frequently asked questions about gout and uncontrolled gout

Understanding gout and uncontrolled gout:

OVERVIEW OF THE DISEASE STATE, CLINICAL BURDEN, AND TREATMENT LANDSCAPE

Clinical Perspectives Presented by:

Clinical Perspectives Presented by:

Program Objectives

Program Objectives